CoChat
Sign Up
Cited by 206Gastrointestinal motility and disordersNausea and vomiting managementGastroesophageal reflux and treatments

The DOI matches its Crossref record; 31 of the 32 references it cites were found in a registry or an index.

Prucalopride in Gastroparesis: A Randomized Placebo-Controlled Crossover Study

Carbone, Florencia, Van den Houte, Karen, Clevers, Egbert, Andrews, Christopher N., Papathanasopoulos, Athanassos, Holvoet, Lieselot, Van Oudenhove, Lukas, Caenepeel, Philip, Arts, Joris, Vanuytsel, Tim, Tack, Jan·2019·American Journal of Gastroenterology
DOI 10.14309/ajg.0000000000000304
Open this paper in CoChat — free account

Abstract

Objectives Prokinetics are considered the preferred treatment option for gastroparesis, but evidence of their efficacy is scarce. Prucalopride, a selective 5-hydroxytryptamine 4 receptor agonist used in the treatment of constipation, is able to enhance the gastric emptying rate. In a double-blind, randomized, placebo-controlled crossover study, we evaluated the efficacy of prucalopride to improve the gastric emptying rate and symptoms in patients with gastroparesis. Methods Thirty-four patients with gastroparesis (28 idiopathic, 7 men, mean age 42 ± 13 years) were evaluated in a double-blind crossover trial of 4-week treatment periods with placebo or prucalopride 2 mg q.d., separated by 2 weeks of washout. The primary end point was the change in symptom severity, assessed by the Gastroparesis Cardinal Symptom Index; secondary end points comprised the Patient Assessment of Upper Gastrointestinal Disorders-Symptom Severity Index, the Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life, and daily diaries, and the gastric emptying rate was assessed by the C-octanoic acid breath test. Results Three patients were lost to follow-up. One serious adverse event occurred (small bowel volvulus in the prucalopride group), and 3 patients dropped out because of adverse events of nausea and headache (all prucalopride). For the entire patient group, compared with placebo, prucalopride significantly improved the total Gastroparesis Cardinal Symptom Index (1.65 ± 0.19 vs 2.28…

Overview

Integrity signals

Registry

Crossref · 10.14309/ajg.0000000000000304

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 32 references

Research works printed but not linked: 1

  1. Carbone, 2014, The effect of prucalopride on gastric accommodation in healthy volunteers, UEG J, 2, 1S

Cited by

Sorted by citations

Items 101–200 of 206

Related

See all

Metadata

Authors
Carbone, F., Van den Houte, K., Clevers, E., Andrews, C. N., Papathanasopoulos, A., Holvoet, L., Van Oudenhove, L., Caenepeel, P., Arts, J., Vanuytsel, T., & Tack, J.
Affiliations
  • KU Leuven (BE)
  • Translational Research Center for Gastrointestinal Disorders (TARGID), University of Leuven, Leuven, Belgium.
Corresponding author
Tack, Jan
ORCID
Venue
American Journal of Gastroenterology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2019-07-08
Volume
114
Issue
8
Pages
1265-1274
ISSN
  • 0002-9270 (ISSN-L)
  • 1572-0241
DOI
10.14309/ajg.0000000000000304
OpenAlex
W2958890085
Cited by
206
References
32
Citations by year
2026: 19 · 2025: 21 · 2024: 25 · 2023: 30 · 2022: 27 · 2021: 39 · 2020: 33 · 2019: 9
FWCI
24.54
Type
journal article
Language
en
Open access
closed
Locations
  • The American Journal of Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
  • Lirias (submittedVersion)
Topics
  • Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
  • Health Sciences › Medicine › Surgery › Nausea and vomiting management
  • Health Sciences › Medicine › Gastroenterology › Gastroesophageal reflux and treatments
Keywords
prucalopride, gastroparesis, prokinetic agents, 5-HT4 receptor agonist, gastric emptying, Gastroparesis Cardinal Symptom Index, quality of life, idiopathic gastroparesis, nausea and vomiting, small bowel volvulus, adverse events, gastric emptying half-time, crossover trial
MeSH terms
Adult, Benzofurans, Breath Tests, Double-Blind Method, Female, Gastric Emptying, Humans, Male, Quality of Life, Severity of Illness Index, Gastroparesis, Cross-Over Studies, Serotonin 5-HT4 Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review